About CUTISS
CUTISS is a Healthcare company based in Zurich (Switzerland) founded in 2017 by Daniela Marino and Fabienne Hartmann-Fritsch. Personalized skin tissue therapy is developed by CUTISS for surgeries. It operates on a Product-as-a-Service model. CUTISS has raised $94.37 million across 13 funding rounds from investors including Zurcher Kantonalbank, European Union and GISEV. Its chief executive, as recorded, is Daniela Marino. CUTISS offers products and services including denovoSkin™. Its focus areas include Biotechnology and Regenerative Medicine. Its legal entity is CUTISS AG.
Company details
Skin tissue therapeutics are pioneered by CUTISS, a TechBio company focused on bioengineering. Personalized therapy, denovoSkin, is manufactured for skin surgeries including burns and reconstructive applications. Solutions are produced at a GMP facility in Zurich, Switzerland, using automated, scalable platforms. The technology supports regenerative medicine, space health research, and industrial bioengineered tissues. Expansion into other tissues like gums and cornea is targeted for accessible treatments.
- Total Equity Funding$94.37M (USD)
in 13 rounds
- Latest Funding Round$39.01M (USD), Series C
Sep 2025
- InvestorsZurcher Kantonalbank
& 9 more
Products & Services of CUTISS
CUTISS offers a comprehensive portfolio of products and services, including denovoSkin™.
Personalized skin tissue therapy is developed for surgeries.
Apps and channels of CUTISS
its YouTube channel CUTISS AG has 94 subscribers and 25 videos.
Videos from CUTISS
The most watched videos on CUTISS's YouTube channel, CUTISS AG (94 subscribers). Click a video to play it here.
More on CUTISS AG.
Funding Insights of CUTISS
CUTISS has successfully raised a total of $94.37M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $39.01 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $94.37M
- Total Rounds 13
- Last Round Series C — $39.01M
- First Round $1.04M
(Sep 2017)
- Investors Count 10
Latest 10 of 13 funding rounds of CUTISS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $39.01M | Series C | – | – | |
| May 2024 | $27.48M | Series C | – | Cherry Bay Capital Group | |
| Jan 2022 | $339,619 | Grant | – | – | – |
| Dec 2020 | $61,412 | Grant | – | – | |
| Oct 2020 | $330,318 | Grant | – | – | |
| Jun 2020 | $19.5M | Series B | – | Giammaria Giuliani | |
| Nov 2019 | $201,630 | Grant | – | – | |
| Oct 2018 | $2.89M | Grant | – | – | – |
| Jun 2018 | $7.33M | Series A | – | Giammaria Giuliani | |
| Apr 2018 | $60,634 | Grant | – | – |
10 investors in total: 9 institutional and 1 angel.
Investors in CUTISS
CUTISS has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, European Union and GISEV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
| yellowstoneholding.ch | ||||
Cherry Bay Capital Group is engaged in wealth advisory and investment services. | cherrybaycapital.com | Monaco, Monaco | ||
Legal and family law services are provided by GISEV. | 2017 | gisev.com | Lugano, Switzerland | |
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank. | 1870 | zkb.ch | Zurich, Switzerland | |
Innovative solutions are supported by the Wyss Foundation for conservation. | wyssfoundation.org | |||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Funds are raised to support research and education at UZH. | uzhfoundation.ch | Zurich, Switzerland | ||
GG Giammaria Giuliani | unknown_cd0c045772014d4b9 | |||
Multispecialty medical services are delivered in Beverwijk, Netherlands. | 1994 | rkz.nl | Beverwijk, Netherlands |
Investor details for CUTISS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CUTISS
13 people are tracked at CUTISS (5 in leadership, 8 in team).
| Name | Role | Group |
|---|---|---|
Daniela Marino | Co-Founder & CEO | Leadership |
Fabienne Hartmann-Fritsch | Co-Founder | Leadership |
Kathi Mujynya | Chief Operating Officer | Leadership |
Vincent Ronfard | Chief Innovative Officer | Leadership |
Joaquin Urdinez | Director Of Operations | Leadership |
Arina Löw | Associate Manager Operations | Team |
Anna-Lena Murphy-Dittrich | Quality Excellence Lead | Team |
Robert Pritchard | Senior Quality Control Specialist | Team |
Laura Bojsen-Møller | QA Associate | Team |
Darjan Andrejc | Senior QA Manager - Team Lead - Deputy Responsible Person (fvp) | Team |
Mei Chien Wong Brawand | Procurement/commercial Associate | Team |
Adeline Beaupoil | Finance Manager | Team |
Nathalie Moro | Production Associate Manager GMP | Team |
Complete people profiles for CUTISS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CUTISS
3 dated milestones of CUTISS across 8 years, from founding to its latest funding, stage changes and deals.
- Founded CUTISS is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series C, of $39.0M.
Web traffic of CUTISS
The website of CUTISS (cutiss.swiss) receives about 7.9K visits a month.
- Monthly visits7.9K
▲ 50.3% vs previous month
Websites whose visitors overlap most with CUTISS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
wanderwego.com | wanderwego.com | 100% | #1,081,152 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cutiss
Complete news archive for CUTISS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CUTISS
CUTISS was founded in 2017.
CUTISS is headquartered in Zurich, Switzerland.
Daniela Marino is the CEO of CUTISS, as recorded in our data. They have also founded this company.
CUTISS is a funded company, having raised a total of $94.37M across 13 funding rounds to date. The company's 1st funding round was a Grant of $60.63K, raised on Sep 2017.
Skin tissue therapeutics are pioneered by CUTISS, a TechBio company focused on bioengineering. Personalized therapy, denovoSkin, is manufactured for skin surgeries including burns and reconstructive applications. Solutions are produced at a GMP facility in Zurich, Switzerland, using automated, scalable platforms. The technology supports regenerative medicine, space health research, and industrial bioengineered tissues. Expansion into other tissues like gums and cornea is targeted for accessible treatments.
CUTISS offers denovoSkin™.
CUTISS has 10 investors. Key investors include Zurcher Kantonalbank, European Union, GISEV, Rode Kruis Ziekenhuis, and Cherry Bay Capital Group.
CUTISS operates through Cutiss Ag.